EFFICACY AND SAFETY OF LURBINECTEDIN (PM1183, ZEPSYRE®) IN SMALL CELL LUNG CANCER (SCLC): RESULTS FROM A PHASE 2 STUDY

ASCO 2018

POSTER1

LURBINECTEDIN (PM01183) WITH DOXORUBICIN (DOX), AN ACTIVE TREATMENT AS SECOND-LINE THERAPY IN SMALL CELL LUNG CANCER (SCLC)

Foster M ASCO 2015

FOSTER2

OVERALL SURVIVAL WITH LURBINECTEDIN PLUS DOXORUBICIN IN RELAPSED SCLC. RESULTS FROM AN EXPANSION COHORT OF A PHASE Ib TRIAL

IASLC. Toronto, 2018

torontoposter

ACTIVITY OF LURBINECTEDIN AS SINGLE AGENT AND IN COMBINATION IN PATIENTS WITH ADVANCED SMALL CELL LUNG CANCER (SCLC)

ESMO 2017

esmo

ACTIVITY AND SAFETY OF THE COMBINATION OF LURBINECTEDIN (PM1183) AND DOXORUBICIN IN RELAPSED SCLC. FINAL RESULTS OF A PHASE LB TRIAL

IASLC Yokohama – Japan 2017

yokohama

Science & Innovation

Our strong commitment to oncology translational research along with our deep understanding of the marine biodiversity of our oceans is placing us at the head of marine biotechnology.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom